Eam Investors, LLC Biocryst Pharmaceuticals Inc Transaction History

Eam Investors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.89 - $17.88 $1.29 Million - $2.91 Million	-162,969 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $1.88 Million - $3.22 Million	162,969 New	162,969 $2.65 Million
Q4 2021 Feb 11, 2022	SELL	$11.18 - $15.46 $1.83 Million - $2.52 Million	-163,324 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $1.23 Million - $1.53 Million	-86,532 Reduced 34.63%	163,324 $2.35 Million
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $2.37 Million - $4.31 Million	249,856 New	249,856 $3.95 Million
Q3 2020 Nov 13, 2020	SELL	$3.43 - $5.53 $1.93 Million - $3.12 Million	-563,961 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.9 - $5.61 $1.07 Million - $3.16 Million	563,961 New	563,961 $2.69 Million
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $837,512 - $2.63 Million	-287,805 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$7.38 - $9.72 $121,563 - $160,107	-16,472 Reduced 5.41%	287,805 $2.34 Million
Q4 2018 Feb 13, 2019	BUY	$6.51 - $9.6 $1.98 Million - $2.92 Million	304,277 New	304,277 $2.46 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.